<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The HLA class II DRB1 antigen DR15 is an important prognostic marker in immune-mediated marrow failure states </plain></SENT>
<SENT sid="1" pm="."><plain>DR15 has also been associated with favorable outcomes (reduced <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> [aGVHD] and relapse) after allogeneic hematopoietic cell transplant </plain></SENT>
<SENT sid="2" pm="."><plain>To elucidate the impact of DR15 on transplantation outcomes, we conducted a retrospective study of 2891 recipients of first allogeneic stem cell transplant from HLA-matched sibling donors for the treatment of <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) between 1990 and 2007 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received conventional myeloablative conditioning, T-replete grafts, and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> plus <z:chebi fb="0" ids="44185">methotrexate</z:chebi>-based GVHD prophylaxis </plain></SENT>
<SENT sid="4" pm="."><plain>DNA-based HLA typing allowed categorization of 732 patients (25.3%) as positive and 2159 patients (74.7%) as negative for DRB1*15:01 or *15:02 (DR15) </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant differences in baseline characteristics between the HLA DR15 positive and negative groups </plain></SENT>
<SENT sid="6" pm="."><plain>In univariate analysis, HLA-DR15 status had no impact on neutrophil engraftment, aGVHD, <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (cGVHD), treatment-related mortality, relapse, disease-free survival, or overall survival (OS) </plain></SENT>
<SENT sid="7" pm="."><plain>In multivariate analysis, DR15 status showed no significant difference in aGVHD, cGVHD, OS, or relapse </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, DR15 status had no impact on major HLA-matched sibling donor hematopoietic cell transplant outcomes in this large and homogenous cohort of patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>